24 March 2022 : Clinical Research
Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
Ying Liao1BCE, Changhua Zhu
DOI: 10.12659/MSM.934493
Med Sci Monit 2022; 28:e934493
Table 1 Comparison of age, course of disease, clinical stage, pathological type, and MMR expression between the 2 groups.
Group | Observation group (n=52) | Control group (n=41) | t/χ2 | p | |
---|---|---|---|---|---|
Age | 46.71±6.42 | 45.22±5.27 | 1.202 | 0.233 | |
Course of the disease | 2.44±0.85 | 2.27±0.98 | 0.919 | 0.361 | |
Clinical-stage (III/IV) | 35/17 | 29/12 | 0.125 | 0.723 | |
Pathological type | Localized type | 18 | 14 | 0.003 | 0.999 |
Diffuse type | 24 | 19 | |||
Polypoid type | 10 | 8 | |||
pMMR/dMMR | 40/12 | 31/10 | 0.022 | 0.882 | |
MSS/MSI-L/MSI-H | 32/8/12 | 26/5/10 | 0.196 | 0.906 | |
Data are presented as mean±standard deviation. |